Combination of the glycoengineered Type II CD20 antibody obinutuzumab (GA101) and The novel Bcl-2 selective Inhibitor GDC-0199 Results in superior In Vitro and In Vivo Anti-tumor activity in models Of B-Cell Malignancies
Sampath D, Herter S, Herting F et al.
Key Points:
Authors investigated efficacy of combination of GA101 or rituximab with GDC-0199 .
GA101 and rituximab in combination with GDC-0199 enhanced cell death.
Implications:
- Combination of GA101 with GDC-0199 results in enhanced cell death and robust anti-tumor efficacy in xenograft models.
View the original abstract on the ASH website.
